• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rheumatol Int . COVID-19 vaccination in autoimmune disease (COVAD) survey protocol

tetano

Editor, Senior Moderator
Rheumatol Int


. 2021 Nov 15.
doi: 10.1007/s00296-021-05046-4. Online ahead of print.
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol


Parikshit Sen[SUP] 1 [/SUP], Latika Gupta[SUP] 2 3 [/SUP], James B Lilleker[SUP] 4 5 [/SUP], Vishwesh Aggarwal[SUP] 6 [/SUP], Sinan Kardes[SUP] 7 [/SUP], Marcin Milchert[SUP] 8 [/SUP], Tamer Gheita[SUP] 9 [/SUP], Babur Salim[SUP] 10 [/SUP], Tsvetelina Velikova[SUP] 11 [/SUP], Abraham Edgar Gracia-Ramos[SUP] 12 [/SUP], Ioannis Parodis[SUP] 13 14 [/SUP], Albert Selva O'Callaghan[SUP] 15 [/SUP], Elena Nikiphorou[SUP] 16 17 [/SUP], Ai Lyn Tan[SUP] 18 19 [/SUP], Lorenzo Cavagna[SUP] 20 [/SUP], Miguel A Saavedra[SUP] 21 [/SUP], Samuel Katsuyuki Shinjo[SUP] 22 [/SUP], Nelly Ziade[SUP] 23 24 [/SUP], Johannes Knitza[SUP] 25 [/SUP], Masataka Kuwana[SUP] 26 [/SUP], Giovanni Cagnotto[SUP] 27 28 [/SUP], Arvind Nune[SUP] 29 [/SUP], Oliver Distler[SUP] 30 [/SUP], Hector Chinoy[SUP] 31 32 33 [/SUP], Vikas Aggarwal[SUP] 34 [/SUP], Rohit Aggarwal[SUP] 35 [/SUP], COVAD Study Group



Collaborators, Affiliations

Abstract

The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.

Keywords: Autoimmune diseases; COVAD; COVID-19; Survey; Vaccination.
 
Back
Top Bottom